SARS-CoV-2 Variant-Specific mRNA Vaccine: Pros and Cons

Area of Science:

• Immunology
• Virology
• Computational Biology

Background:

• Emerging severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants pose challenges to vaccine efficacy.
• Assessing variant-specific vaccine potential is crucial for public health.

Purpose of the Study:

• To compare the immune response potential of Delta and Omicron variant-specific mRNA vaccines.
• To identify the most suitable variant for mRNA vaccine development against SARS-CoV-2.

Main Methods:

• In silico prediction of B cell and T cell epitopes and population coverage of spike (S) glycoproteins.
• Molecular docking of S protein and receptor-binding domain (RBD) with toll-like receptors (TLRs) and angiotensin-converting-enzyme 2 (ACE2).
• mRNA secondary structure prediction and immune response simulation using C-ImmSim.

Main Results:

• Delta variant exhibited stronger binding affinity to major histocompatibility complex (MHC) II alleles and lower binding energy with ACE2 and TLRs compared to Omicron.
• Immune simulations indicated robust responses, including elevated cytotoxic T lymphocytes, helper T lymphocytes, and memory cells.
• No significant difference in predicted B cell and T cell epitopes between Delta and Omicron variants.

Conclusions:

• The Delta variant demonstrates superior binding interactions and is recommended for mRNA vaccine construction.
• mRNA vaccine constructs show capacity for eliciting robust immune responses against SARS-CoV-2 variants.
• Further studies are warranted to validate the efficiency of the proposed Delta variant-based mRNA vaccine design.